| Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR−/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in … MK Brimnes, AJ Vangsted, LM Knudsen, P Gimsing, AO Gang, ... Scandinavian journal of immunology 72 (6), 540-547, 2010 | 276 | 2010 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 236 | 2021 |
| Genome-wide association study identifies multiple susceptibility loci for multiple myeloma JS Mitchell, N Li, N Weinhold, A Försti, M Ali, M Van Duin, G Thorleifsson, ... Nature communications 7 (1), 12050, 2016 | 193 | 2016 |
| Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma P Sonneveld, MA Dimopoulos, M Boccadoro, H Quach, PJ Ho, M Beksac, ... New England Journal of Medicine 390 (4), 301-313, 2024 | 146 | 2024 |
| Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) E Terpos, M Engelhardt, G Cook, F Gay, MV Mateos, ... Leukemia 34 (8), 2000-2011, 2020 | 139 | 2020 |
| Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised … P Gimsing, K Carlson, I Turesson, P Fayers, A Waage, A Vangsted, ... The lancet oncology 11 (10), 973-982, 2010 | 136 | 2010 |
| Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma M Went, A Sud, A Försti, BM Halvarsson, N Weinhold, S Kimber, ... Nature communications 9 (1), 3707, 2018 | 126 | 2018 |
| Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma B Swaminathan, G Thorleifsson, M Jöud, M Ali, E Johnsson, R Ajore, ... Nature communications 6 (1), 7213, 2015 | 94 | 2015 |
| Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study R Sørrig, TW Klausen, M Salomo, AJ Vangsted, B Østergaard, ... European journal of haematology 97 (3), 303-309, 2016 | 72 | 2016 |
| Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma … MO Holmström, P Gimsing, N Abildgaard, NF Andersen, C Helleberg, ... American journal of hematology 90 (4), E73-4, 2015 | 67 | 2015 |
| Immunochemical Detection of a Small Cell Lung Cancer-associated Ganglioside (FucGM1) Antigen in Serum AJ Vangsted, H Clausen, TB Kjeldsen, T White, B Sweeney, S Hakomori, ... Cancer research 51 (11), 2879-2884, 1991 | 62 | 1991 |
| Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population R Sørrig, TW Klausen, M Salomo, AJ Vangsted, UC Frølund, KT Andersen, ... PLoS One 12 (12), e0188988, 2017 | 59 | 2017 |
| Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow … A Vangsted, P Gimsing, TW Klausen, BA Nexø, H Wallin, P Andersen, ... International journal of cancer 120 (5), 1036-1045, 2007 | 59 | 2007 |
| Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t (11; 14) NJ Bahlis, R Baz, SJ Harrison, H Quach, SJ Ho, AJ Vangsted, T Plesner, ... Journal of Clinical Oncology 39 (32), 3602-3612, 2021 | 58 | 2021 |
| The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study H Gregersen, AJ Vangsted, N Abildgaard, NF Andersen, RS Pedersen, ... Cancer medicine 6 (7), 1807-1816, 2017 | 58 | 2017 |
| The Danish national multiple myeloma registry P Gimsing, MO Holmström, TW Klausen, NF Andersen, H Gregersen, ... Clinical epidemiology, 583-587, 2016 | 55 | 2016 |
| Oxytocin and vasopressin binding sites in human and bovine ovaries AR Fuchs, O Behrens, H Helmer, A Vangsted, M Ivanisevic, J Grifo, ... American journal of obstetrics and gynecology 163 (6), 1961-1967, 1990 | 55 | 1990 |
| Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients E Ziv, E Dean, D Hu, A Martino, D Serie, K Curtin, D Campa, B Aftab, ... Nature communications 6 (1), 7539, 2015 | 52 | 2015 |
| First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). PG Richardson, AJ Vangsted, K Ramasamy, S Trudel, J Martínez, ... Journal of Clinical Oncology 38 (15_suppl), 8500-8500, 2020 | 49 | 2020 |
| Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma PG Richardson, S Trudel, R Popat, MV Mateos, AJ Vangsted, ... New England Journal of Medicine 389 (11), 1009-1022, 2023 | 43 | 2023 |
